Abstract
BACKGROUND AND AIM: Heart failure is a common condition that affects millions of people worldwide. The aim of this study was to evaluate the 6-month effect of sacubitril-valsartan (SV) compared to angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) on left ventricular ejection fraction (LVEF) in heart failure patients. METHODS: This is a clinical trial involving heart failure patients (n = 225) referred to Farshchian Heart Hospital in Hamadan-Iran from April to September 2023. The patients were randomly assigned to three groups receiving SV (n = 75), ACEI (n = 75), and ARB (n = 75). In all three treatment groups, LVEF was checked and compared by echocardiography before the treatment and 6 months after the treatment. RESULTS: The mean scores of an increase in EF compared to before treatment in the SV, ACEI, and ARB groups were 1.73 ± 2.78%, 0.69 ± 1.93%, and 0.14 ± 1.42%, respectively (P < .001) groups (29.3 vs. 6.7 and 12.7%, P < .001). In addition, no significant difference was observed between the three groups in terms of mortality. The number of hospitalizations and the duration of hospitalization were lower in the sacubitril-valsartan group than in the ACEI and ARB groups. CONCLUSION: In this study, SV was shown to be superior to ACEI and ARB in improving LVEF in heart failure patients at 6 months follow-up. These findings highlight the potential benefits of SV in the management of heart failure.